Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Go back to Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Canaccord Genuity Reiterates Buy Rating on Delcath Systems (DCTH)

March 27, 2024 8:09 AM EDT

Canaccord Genuity analyst Bill Maughan reiterated a Buy rating and $21.00 price target on Delcath Systems (NASDAQ: DCTH).

The analyst commented, "Delcath reported 4Q23 results this morning and gave an update on the early launch of Hepzato, which came available in January for the treatment of metastatic uveal melanoma... More